Loading organizations...
Loading organizations...
Inner Cosmos is a technology company.
Inner Cosmos develops "The Digital Pill," a minimally invasive, embedded Brain-Computer Interface designed to treat depression. This innovative neurotechnology precisely reads and stimulates brain networks to rebalance them. The device, an in-bone implant requiring only a one-hour outpatient procedure, offers therapeutic benefits comparable to or exceeding transcranial magnetic stimulation, integrating seamlessly and unobtrusively into users' daily lives without the need for frequent clinic visits.
The company was conceived in 2016 when Meron Gribetz, a visionary in neuroscience and engineering, joined forces with Dr. Eric Leuthardt, a pioneer in BCI, Dr. Dan Moran, an expert in ECoG, and Ted Kucklick, a seasoned product developer. Their collective insight was to transform complex brain stimulation into an accessible, user-friendly device, leveraging their deep experience in neurotechnology and spatial computing to address significant unmet needs in mental health.
Inner Cosmos targets individuals battling depression, offering a discrete and effective therapeutic option for those seeking mental wellness. The company’s long-term vision centers on helping humanity achieve widespread mental health by making its advanced brain treatment universally accessible. It aims to provide a transformative solution that allows individuals to regain control over their mood and improve their overall quality of life.
Inner Cosmos has raised $11.0M across 2 funding rounds.
Inner Cosmos has raised $11.0M in total across 2 funding rounds.
Inner Cosmos has raised $11.0M in total across 2 funding rounds.
Inner Cosmos's investors include lool ventures, KittyHawk Ventures, Loup Ventures.
Inner Cosmos is a neurotechnology company developing a pioneering brain-computer interface (BCI) called the "Digital Pill," designed to treat depression and other cognitive disorders through non-invasive, precise micro-stimulations. The Digital Pill is a tiny implant placed just under the skin that rebalances brain networks without requiring invasive brain surgery. Inner Cosmos targets individuals suffering from depression, the most widespread chronic mental health disorder globally, aiming to provide a new form of digital neuro-medicine that integrates seamlessly into patients' lifestyles. The company generates revenue from device sales, implantation services, and potentially ongoing subscription-based monitoring and adjustments[1][3][5].
Founded in 2022, Inner Cosmos was established by a team including notable figures such as Meron Gribetz, an augmented reality pioneer, and Ed Boyden, a leader in optogenetics and temporal interference. Their combined expertise in neurotechnology and bioelectronic medicine shaped the company’s mission to revolutionize psychiatric care. The idea emerged from the need for a less invasive, more precise treatment for mood disorders, leading to the development of the Digital Pill. Early clinical trials have shown promising results, with patients reporting significant mood improvements and remission of depressive symptoms, marking pivotal moments in validating the technology[1][4][5].
Inner Cosmos rides the growing trend of bioelectronic medicine and digital therapeutics, which aim to treat diseases through electrical modulation rather than pharmaceuticals. The timing is critical as mental health disorders, particularly depression, represent a massive unmet medical need with limited effective treatments. Advances in neurotechnology, miniaturization, and brain-computer interfaces create favorable market conditions for Inner Cosmos’s approach. By introducing a non-invasive, precise, and personalized therapy, Inner Cosmos is poised to influence the broader mental health ecosystem, potentially shifting paradigms from drug-based to device-based treatments and fostering innovation in neuropsychiatric care[1][5].
Looking ahead, Inner Cosmos is positioned to expand its Digital Pill platform to address additional cognitive disorders beyond depression, leveraging ongoing clinical trials and regulatory approvals. Trends such as increasing acceptance of digital health solutions, advances in neurotechnology, and growing mental health awareness will shape its trajectory. The company’s influence may grow as it partners with healthcare providers and insurers to integrate bioelectronic therapies into standard care. Continued innovation and clinical validation will be key to scaling adoption and transforming psychiatric treatment paradigms, reinforcing Inner Cosmos’s role as a leader in digital neuro-medicine[1][5].
Inner Cosmos has raised $11.0M across 2 funding rounds. Most recently, it raised $10.0M Seed in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 30, 2022 | $10.0M Seed | lool ventures | KittyHawk Ventures, Loup Ventures |
| Nov 1, 2018 | $1.0M Seed | KittyHawk Ventures |